US equities
|
NVDA
$239.24
▲+0.14%
MU
$1,045.56
▼-1.73%
SPCX
$171.92
▲+0.49%
AMD
$649.42
▲+2.80%
MRVL
$287.01
▲+5.81%
AVGO
$375.81
▲+3.67%
INTC
$112.50
▼-3.18%
MSFT
$529.30
▲+0.78%
NVDA
$239.24
▲+0.14%
MU
$1,045.56
▼-1.73%
SPCX
$171.92
▲+0.49%
AMD
$649.42
▲+2.80%
MRVL
$287.01
▲+5.81%
AVGO
$375.81
▲+3.67%
INTC
$112.50
▼-3.18%
MSFT
$529.30
▲+0.78%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
NanoViricides, Inc. Common Stock
(NY:
NNVC
)
1.400
-0.050 (-3.45%)
Official Closing Price
Updated: 8:00 PM EDT, Oct 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about NanoViricides, Inc. Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive
October 29, 2025
Via
ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present at PODD 2025 Conference in Boston
October 27, 2025
Via
Investor Brand Network
Topics
Intellectual Property
NanoViricides to Present at the PODD 2025 Conference in Boston on October 27
October 27, 2025
Via
ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Reports Strong Antiviral and Lung-Protective Activity of NV-387 Against Measles
October 23, 2025
Via
Investor Brand Network
Topics
Intellectual Property
In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides
October 22, 2025
Via
ACCESS Newswire
A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus
October 20, 2025
Via
ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Featured in Analyst Report Highlighting Dual-Track Clinical Strategy for NV-387
October 15, 2025
Via
Investor Brand Network
Topics
Intellectual Property
NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses
October 15, 2025
Via
ACCESS Newswire
NanoViricides, Inc. Has Filed its Annual Report
September 30, 2025
Via
ACCESS Newswire
RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025
September 11, 2025
Via
ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present at LSX World Congress 2025
September 10, 2025
Via
Investor Brand Network
Topics
Intellectual Property
NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025
September 09, 2025
Via
ACCESS Newswire
NanoViricides Reports NV-387’s Anti-Inflammatory Effects Could Combat Viral-Induced Cancer Resurgence
August 27, 2025
Via
AB Newswire
A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials
August 18, 2025
Via
ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Highlights NV-387 as Potential Treatment for Growing Measles Outbreaks
July 30, 2025
Via
Investor Brand Network
Topics
Intellectual Property
Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides
July 30, 2025
Via
ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Highlights NV-387’s Broad Antiviral Potential and Strategic Value for Pandemic Preparedness
July 23, 2025
Via
Investor Brand Network
Topics
Intellectual Property
NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value
July 23, 2025
Via
ACCESS Newswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
July 22, 2025
Via
Benzinga
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Reports Breakthrough Measles Drug Success in Humanized Animal Study
July 21, 2025
Via
Investor Brand Network
Topics
Intellectual Property
Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides
July 21, 2025
Via
ACCESS Newswire
BioMedNewsBreaks — NanoViricides, Inc. (NYSE American: NNVC) Highlights MPox Drug Progress as WHO Extends Global Health Emergency
July 16, 2025
Via
Investor Brand Network
Topics
Intellectual Property
WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides
July 16, 2025
Via
ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Finalizes Adaptive Trial Design for MPox Drug NV-387
July 14, 2025
Via
Investor Brand Network
Topics
Intellectual Property
Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides
July 14, 2025
Via
ACCESS Newswire
There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate
July 01, 2025
Via
ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights NV-387 as Broad-Spectrum Antiviral Candidate for COVID and Bird Flu Preparedness
June 18, 2025
Via
Investor Brand Network
Topics
Intellectual Property
With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan
June 18, 2025
Via
ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Advances Measles Drug Program Amid Rising Global Outbreaks
June 04, 2025
Via
Investor Brand Network
Topics
Intellectual Property
NanoViricides Measles Drug Development Animal Study is Imminent
June 04, 2025
Via
ACCESS Newswire
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
